骨质疏松的健康管理发展现状及挑战

管晶晶; 陈宇; 汤华冬; 周平辉

doi:10.16766/j.cnki.issn.1674-4152.002153

骨质疏松的健康管理发展现状及挑战

doi: 10.16766/j.cnki.issn.1674-4152.002153

1.
蚌埠医学院第一附属医院健康管理中心，安徽蚌埠 233004
2.
蚌埠医学院第一附属医院整形外科，安徽蚌埠 233004
3.
蚌埠医学院临床医学院，安徽蚌埠 233030
4.
蚌埠医学院第一附属医院骨科，安徽蚌埠 233004

基金项目:

国家自然科学基金项目 31700854

安徽省教育厅自然科学重点项目 KJ2018A1011

详细信息

通讯作者:
周平辉，E-mail：zphdoctor@126.com

中图分类号: R681
计量
- 文章访问数: 408
- HTML全文浏览量: 180
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-11
- 网络出版日期: 2022-02-15

Current status and challenges of health management for osteoporosis

1.
Health Management Centre, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 骨质疏松是引起老年人骨质疏松性骨折的主要原因，严重影响患者的生活质量、增加经济负担。引起骨质疏松的主要原因包括骨密度下降、骨组织显微结构的破坏及骨强度减弱等。目前针对骨密度下降这一原因的主要治疗手段是使用抗骨吸收药物(如双膦酸盐类药物、降钙素)、促进骨形成药物(甲状旁腺激素)以及某些中药等，然而药物治疗效果并不理想。尽管可以通过手术进行干预，但依旧存在诸多术后并发症。近年来随着三级预防思想的树立，从一级预防的角度针对高危人群来进行骨质疏松的健康管理成为当前预防骨质疏松症及相关骨折的主流方法。本文主要从骨质疏松健康管理的来源与患者和医务人员的相互关系2个方面简要介绍骨质疏松健康管理的一些措施及其在当前发展中所遇到的挑战。此外，绝经后女性的骨质疏松症主要是由于雌激素减少导致骨密度下降，因而在预防措施上与老年性骨质疏松有所不同，予以分开阐述。进一步的发展目前需要解决我国三级诊疗体系尚不完善的现状并制定出更科学的骨质疏松评定标准以及加强患者对健康管理方案中饮食和生活习惯的依从性等。此外，从雌激素的类型、剂量、持续使用时间以及个体情况等方面改善并发展雌激素在围绝经期女性骨质疏松健康管理中的应用，最终发挥健康管理在骨质疏松症及相关骨折中的一级预防作用。
- 骨质疏松 /
- 健康管理 /
- 绝经后女性 /
- 雌激素 /
- 综述
Abstract: Osteoporosis is the main cause of osteoporosis fracture in the elderly, which seriously affects the quality of life of patients and increases economic burden. The main causes of osteoporosis include the decrease of bone density, the destruction of bone microstructure and the decrease of bone strength. At present, the main treatment for decreased bone mineral density is to use anti-bone absorption drugs (such as bisphosphonates, calcitonin), bone formation-promoting drugs (parathyroid hormone) and some traditional Chinese medicine. However, the effect of drug treatment is not ideal. Despite surgical intervention, many complications exist. In recent years, with the establishment of the idea of three-level prevention, the health management of osteoporosis from the perspective of one-level prevention has become the mainstream method to prevent osteoporosis and related fractures. In this study, the source of osteoporosis health management and the relationship between patients and medical staff are introduced briefly, including some measures of osteoporosis health management and the challenges in the current development. In addition, the osteoporosis of postmenopausal women is mainly caused by the decrease of bone density caused by the loss of oestrogen. Thus, its preventive measures are different from those of senile osteoporosis, which should be described separately. The current situation of the three-level diagnosis and treatment system in China needs to be solved, a more scientific evaluation standard of osteoporosis should be developed, and patients' compliance with diet and living habits in the health management plan need to be strengthened. In addition, we should improve and develop the application of oestrogen in the health management of perimenopausal women's osteoporosis from the type, dose, duration and individual situation of estrogen, and finally play the primary preventive role of health management in osteoporosis and related fractures.
- Osteoporosis /
- Health management /
- Postmenopausal women /
- Oestrogen /
- Review

HTML全文

参考文献(41)

[1]	LESLIE W D, MORIN S N. Osteoporosis epidemiology 2013: Implications for diagnosis, risk assessment, and treatment[J]. Curr Opin Rheumatol, 2014, 26(4): 440-446. doi: 10.1097/BOR.0000000000000064
[2]	CHEN P, LI Z, HU Y. Prevalence of osteoporosis in China: A meta-analysis and systematic review[J]. BMC Public Health, 2016, 16(1): 1039. doi: 10.1186/s12889-016-3712-7
[3]	罗令, 孙晓峰, 皮丕喆, 等. 近10年来我国中老年人群骨质疏松症患病率的荟萃分析[J]. 中国骨质疏松杂志, 2018, 24(11): 1415-1420. doi: 10.3969/j.issn.1006-7108.2018.11.005
[4]	KHOSLA S, HOFBAUER L C. Osteoporosis treatment: Recent developments and ongoing challenges[J]. Lancet Diabetes Endocrinol, 2017, 5(11): 898-907. doi: 10.1016/S2213-8587(17)30188-2
[5]	ZHANG N D, HAN T, HUANG B K, et al. Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery[J]. J Ethnopharmacol, 2016, 189: 61-80. doi: 10.1016/j.jep.2016.05.025
[6]	RUSSELL L A. Osteoporosis and orthopedic surgery: Effect of bone health on total joint arthroplasty outcome[J]. Curr Rheumatol Rep, 2013, 15(11): 371. doi: 10.1007/s11926-013-0371-x
[7]	温勇. 健康管理对中老年骨质疏松症患者生活质量影响的Meta分析[D]. 广州: 广州中医药大学, 2016.
[8]	潘小红. 老年骨质疏松患者饮食行为干预及健康管理研究[J]. 名医, 2018(9): 40. https://www.cnki.com.cn/Article/CJFDTOTAL-MGYI201809032.htm
[9]	白颖, 杨明珠, 杨雪, 等. 骨质疏松骨折患者的健康管理及效果分析[J]. 中国骨质疏松杂志, 2014, 20(12): 1450-1452. doi: 10.3969/j.issn.1006-7108.2014.12.017
[10]	CHANG H C, HSIEH C F, LIN Y C, et al. Does coffee drinking have beneficial effects on bone health of Taiwanese adults? A longitudinal study[J]. BMC Public Health, 2018, 18(1): 1273. doi: 10.1186/s12889-018-6168-0
[11]	毕娜, 丁红, 苏天娇, 等. 社区骨质疏松患者饮食行为及健康管理策略[J]. 中国骨质疏松杂志, 2017, 23(4): 452-455. doi: 10.3969/j.issn.1006-7108.2017.04.007
[12]	许倩, 宋志雪, 陈长香, 等. 早骨质疏松老年人自我健康管理行为状况分析[J]. 中国骨质疏松杂志, 2016, 22(8): 1012-1015. doi: 10.3969/j.issn.1006-7108.2016.08.015
[13]	EXPERT PANEL ON MUSCULOSKELETAL IMAGING, WARD R J, ROBERTS C C, et al. ACR Appropriateness Criteria? Osteoporosis and bone mineral density[J]. J Am Coll Radiol, 2017, 14(5S): S189-S202. http://f.i-md.com/medinfo/material/012/4eb0148f44aee4f554e17012/4eb014ad44aee4f554e17015.pdf
[14]	张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1007-1010. doi: 10.3969/j.issn.1006-7108.2014.09.001
[15]	SALE J E, HAWKER G, CAMERON C, et al. Perceived messages about bone health after a fracture are not consistent across healthcare providers[J]. Rheumatol Int, 2015, 35(1): 97-103. doi: 10.1007/s00296-014-3079-y
[16]	李夏珀, 覃素娇, 谈佳, 等. 基于唤醒教育的健康管理对骨质疏松患者健康信念、行为及骨密度的影响[J]. 广西医学, 2018, 40(15): 1761-1764. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYX201815045.htm
[17]	SCOTT T A, BEVERIDGE A, NI CHRONIN D. Suboptimal bone protection in geriatric inpatients and effect of a simple educational and mnemonic strategy[J]. Australas J Ageing, 2016, 35(3): E36-E39. doi: 10.1111/ajag.12320
[18]	GOODE J V, SWIGER K, BLUML B M. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: Findings from Project ImPACT: Osteoporosis[J]. J Am Pharm Assoc, 2004, 44(2): 152-160. doi: 10.1331/154434504773062609
[19]	NIK J, LAI P S, NG C J, et al. A qualitative study of community pharmacists' opinions on the provision of osteoporosis disease state management services in Malaysia[J]. BMC Health Serv Res, 2016, 16(1): 448. doi: 10.1186/s12913-016-1686-x
[20]	ZHANG J, LIU X, LI H, et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/qkt signaling pathway[J]. Stem Cell Res Ther, 2016, 7(1): 136. doi: 10.1186/s13287-016-0391-3
[21]	LIANG J, CHEN C, LIU H, et al. Gossypol promotes bone formation in ovariectomy-induced osteoporosis through regulating cell apoptosis[J]. Biomed Res Int, 2018: 3635485. http://downloads.hindawi.com/journals/bmri/2018/3635485.pdf
[22]	LI T, JIANG S, LU C, et al. Melatonin: Another avenue for treating osteoporosis?[J]. J Pineal Res, 2019, 66(2): e12548. doi: 10.1111/jpi.12548
[23]	BLACK D M. Postmenopausal osteoporosis[J]. N Engl J Med, 2016, 374(21): 2096-2097.
[24]	崔燎. 骨质疏松症的药物防治: 难点与展望[J]. 广东医科大学学报, 2020, 38(2): 127-133. doi: 10.3969/j.issn.1005-4057.2020.02.001
[25]	FINKELSTEIN J S, WYLAND J J, LEE H. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis[J]. J Clin Endocrinol Metab, 2010, 95(4): 1838-1845. doi: 10.1210/jc.2009-1703
[26]	SAAG K G, SHANE E, BOONEN S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis[J]. N Engl J Med, 2007, 357(20): 2028-2039. doi: 10.1056/NEJMoa071408
[27]	COMPSTON J, COOPER A, COOPER C, et al. UK clinical guideline for the prevention and treatment of osteoporosis[J]. Arch Osteoporos, 2017, 12(1): 43. doi: 10.1007/s11657-017-0324-5
[28]	LEDER B Z, NEER R M, WYLAND J J, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis[J]. J Clin Endocrinol Metab, 2009, 94(8): 2915-2921. doi: 10.1210/jc.2008-2630
[29]	LORENTZON M. Treating osteoporosis to prevent fractures: current concepts and future developments[J]. J Intern Med, 2019, 285(4): 381-394. doi: 10.1111/joim.12873
[30]	刘清阁, 马晓勇, 郭志学, 等. 金乌骨通对预防绝经女性骨质疏松性骨折的疗效研究[J]. 中国医药导刊, 2014, 16(12): 1501-1504. doi: 10.3969/j.issn.1009-0959.2014.12.028
[31]	梁玲玲, 李璐兵, 刘涛. 阿仑膦酸钠预防妇女绝经后脆性骨折效果的Meta分析[J]. 新疆医科大学学报, 2016, 39(4): 460-463. doi: 10.3969/j.issn.1009-5551.2016.04.019
[32]	宋永进, 应锦河. 阿托伐他汀联合雌激素在绝经期骨质疏松女性患者中的应用价值[J]. 中华全科医学, 2016, 14(9): 1485-1487. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201609019.htm
[33]	谢炎秋, 蒋本泰. 唑来膦酸与替勃龙治疗绝经后骨质疏松疗效比较及对骨折的预防作用[J]. 实用药物与临床, 2014, 17(7): 918-920. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC201407031.htm
[34]	LEVIN V A, JIANG X, KAGAN R. Estrogen therapy for osteoporosis in the modern era[J]. Osteoporos Int, 2018, 29(5): 1049-1055. doi: 10.1007/s00198-018-4414-z
[35]	GAMBACCIANI M, LEVANCINI M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis[J]. Prz Menopauzalny, 2014, 13(4): 213-220. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=98177781&site=ehost-live
[36]	KOMM B S, MORGENSTERN D, A YAMAMOTO L, et al. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women[J]. Expert Rev Clin Pharmacol, 2015, 8(6): 769-784. doi: 10.1586/17512433.2015.1099432
[37]	MANSON J E, CHLEBOWSKI R T, STEFANICK M L, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials[J]. JAMA, 2013, 310(13): 1353-1368. doi: 10.1001/jama.2013.278040
[38]	CHLEBOWSKI R T, ANDERSON G L, GASS M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women[J]. JAMA, 2010, 304(15): 1684-1692. doi: 10.1001/jama.2010.1500
[39]	TREMOLLIERES F. Assessment and hormonal management of osteoporosis[J]. Climacteric, 2019, 22(2): 122-126. doi: 10.1080/13697137.2018.1555582
[40]	PASSOS-SOARES J S, VIANNA M I P, GOMES-FILHO I S, et al. Association between osteoporosis treatment and severe periodontitis in postmenopausal women[J]. Menopause, 2017, 24(7): 789-795. doi: 10.1097/GME.0000000000000830
[41]	DODD D Z, ROWE D J. The relationship between postmenopausal osteoporosis and periodontal disease[J]. J Dent Hyg, 2013, 87(6): 336-344. http://jdh.adha.org/content/87/6/336.full.pdf